LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Newly Identified Oncogene Links Amino Acids to Colorectal Cancer Development

By LabMedica International staff writers
Posted on 02 Nov 2014
Print article
Cancer researchers have identified a novel oncogene—and possible drug target—that promotes development of colorectal cancer by interacting with amino acids to activate the pro-cancer mTORC1 signaling complex.

mTOR (mammalian target of rapamycin) is a master regulator of protein synthesis that under ordinary conditions induces cells to grow and divide. In situations of severe nutrient deprivation mTOR closes down protein synthesis so that the cell can conserve energy. However, in cancer cells the mTOR pathway misfires and signals tumor cells to grow, divide, undergo metastasis, and invade new, healthy tissues.

Investigators at Rutgers University (New Brunswick, NJ, USA) have been looking at the interaction between amino acids and the small GTPase enzyme Rab1A, which is a key switch for amino acid signaling.

They reported in the October 13, 2014, online edition of the journal Cancer Cell that amino acids activated Rab1A, which then stimulated Rheb (another small GTPase) to interact with the mTORC1 complex in the cells' Golgi apparatus. They found that Rab1A overexpression promoted mTORC1 signaling and oncogenic growth in an amino acid- and mTORC1-dependent manner. Blocking Rab1A activity selectively inhibited oncogenic growth of Rab1-overexpressing cancer cells. Furthermore, Rab1A was found to be overexpressed in colorectal cancer, which was correlated with elevated mTORC1 signaling, tumor invasion, progression, and poor prognosis. In contrast, overexpression of Rab1A increased sensitivity of cancer cells toward the drug rapamycin, which blocks the growth-stimulating effect of mTORC1.

Senior author Dr. X. F. Steven Zheng, professor of pharmacology at Rutgers University, said, “In further elucidating the role Rab1A plays in amplifying amino acid signaling, we can further understand this impact on the mTORC1 protein. Especially since elevated levels of mTORC1 signaling is found in colorectal cancer, new therapy options targeted toward mTORC1 can be explored.”

Related Links:

Rutgers University



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more